Spark Therapeutics, Inc.

Spark Therapeutics, Inc. develops gene therapies for genetic diseases. Its products include LUXTURNA voretigene neparvovec for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company also provides gene therapy product candidates that comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for haemophilia B. In addition, it develops liver-directed gene therapies. The company was incorporated in 2013 and is based in Philadelphia, Pennsylvania. Spark Therapeutics, Inc. operates as a subsidiary of Roche Holdings, Inc.